The trajectory of companies tied to Viagra's past presents a challenging investment landscape. While the initial surge generated substantial profits , generic copies have significantly diminished market share . Investing in related pharmaceutical firms now requires a thorough assessment of patent rights , evolving patient changes, and the prospect